Sagimet Biosciences (SGMT) has joined the Russell 3000 and Russell 2000 indexes, effective Monday, as part of the 2026 Russell Indexes reconstitution, the company said on the same day.
The company said it has capital in place to fund its programs through 2028, including a planned phase 3 trial of denifanstat in moderate to severe acne, expected in H2.
Price: $7.20, Change: $+0.14, Percent Change: +1.91%